Medications for Renal Cell Carcinoma
Other names: Adenocarcinoma of renal cells; Cancer, Hypernephroma; Cancer, Kidney; Cancer, Renal; Cancer, Renal Cell Carcinoma; Hypernephroma; Kidney Cancer; Renal Cancer
About Renal Cell Carcinoma: Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type of kidney cancer in adults
See also: sub-topics
Drugs Used to Treat Renal Cell Carcinoma
The following list of medications are in some way related to, or used in the treatment of this condition.
Drug name | Rx / OTC | Pregnancy | CSA | Alcohol | Reviews | Rating | Popularity |
---|---|---|---|---|---|---|---|
Cabometyx | D | N | Add review | Rate | |||
Generic name: cabozantinib systemic Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
cabozantinib | D | N | Add review | Rate | |||
Generic name: cabozantinib systemic Brand name: Cabometyx Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
capecitabine Off Label | D | N | Add review | Rate | |||
Generic name: capecitabine systemic Drug class: antimetabolites For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information Off Label: Yes |
|||||||
erlotinib Off Label | D | N | Add review | Rate | |||
Generic name: erlotinib systemic Drug class: EGFR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph Off Label: Yes |
|||||||
lenvatinib | N | Add review | Rate | ||||
Generic name: lenvatinib systemic Brand name: Lenvima Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
Lenvima | N | Add review | Rate | ||||
Generic name: lenvatinib systemic Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Mvasi | C | N | Add review | Rate | |||
Generic name: bevacizumab systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects |
|||||||
peginterferon alfa-2b Off Label | C | N | Add review | Rate | |||
Generic name: peginterferon alfa-2b systemic Drug class: antineoplastic interferons, antiviral interferons For consumers: dosage, interactions, For professionals: A-Z Drug Facts Off Label: Yes |
|||||||
Opdivo | N | 1 review |
1.0
|
||||
Generic name: nivolumab systemic Drug class: Anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
nivolumab | N | 4 reviews |
5.0
|
||||
Generic name: nivolumab systemic Brand name: Opdivo Drug class: Anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
axitinib | D | N | Add review |
6.0
|
|||
Generic name: axitinib systemic Brand name: Inlyta Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
Inlyta | D | N | Add review |
6.0
|
|||
Generic name: axitinib systemic Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Afinitor | D | N | 1 review |
7.0
|
|||
Generic name: everolimus systemic Drug class: mTOR inhibitors, selective immunosuppressants For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
everolimus | D | N | 1 review |
7.0
|
|||
Generic name: everolimus systemic Brand name: Afinitor Drug class: mTOR inhibitors, selective immunosuppressants For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
medroxyprogesterone Off Label | X | N | 1 review |
7.0
|
|||
Generic name: medroxyprogesterone systemic Drug class: hormones/antineoplastics, contraceptives, progestins For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information Off Label: Yes |
|||||||
sunitinib | D | N | 21 reviews |
7.0
|
|||
Generic name: sunitinib systemic Brand name: Sutent Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
Sutent | D | N | 17 reviews |
7.0
|
|||
Generic name: sunitinib systemic Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Avastin | C | N | 1 review |
8.0
|
|||
Generic name: bevacizumab systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
bevacizumab | C | N | 1 review |
8.0
|
|||
Generic name: bevacizumab systemic Brand names: Avastin, Mvasi Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
pazopanib | D | N | 49 reviews |
8.0
|
|||
Generic name: pazopanib systemic Brand name: Votrient Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
Votrient | D | N | 43 reviews |
8.0
|
|||
Generic name: pazopanib systemic Drug class: VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
temsirolimus | D | N | 1 review |
9.0
|
|||
Generic name: temsirolimus systemic Brand name: Torisel Drug class: mTOR inhibitors For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
Torisel | D | N | 1 review |
9.0
|
|||
Generic name: temsirolimus systemic Drug class: mTOR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
aldesleukin | C | N | 1 review |
10
|
|||
Generic name: aldesleukin systemic Brand name: Proleukin Drug class: miscellaneous antineoplastics, interleukins For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
Nexavar | D | N | 2 reviews |
10
|
|||
Generic name: sorafenib systemic Drug class: multikinase inhibitors, VEGF/VEGFR inhibitors For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Topics under Renal Cell Carcinoma
- Wilms' Tumor (10 drugs)
Learn more about Renal Cell Carcinoma
Micromedex® Care Notes
Symptoms and treatments
Mayo Clinic Reference
Legend
Off Label | This medication may not be approved by the FDA for the treatment of this condition. |
---|
Prescription Only / Over the Counter | |
---|---|
Rx | Prescription Only |
OTC | Over the Counter |
Rx/OTC | Prescription or Over the Counter |
Pregnancy | |
---|---|
A | Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters). |
B | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women. |
C | Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
D | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
X | Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits. |
N | FDA has not classified the drug. |
Controlled Substances Act Schedule | |
---|---|
N | Is not subject to the Controlled Substances Act. |
1 | Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision. |
2 | Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence. |
3 | Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
4 | Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
5 | Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Alcohol | |
---|---|
X | Interacts with Alcohol. |